Experimental antibody combo shows promise against tough cancers
NCT ID NCT05307874
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help control the disease, but more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICT01 (an antibody) combined with low-dose interleukin-2 (IL-2) and optionally pembrolizumab
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to everyone. Side effects are possible, and the combination may not shrink tumors in most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IUCT Oncopole Claudius Regaud
Toulouse, France
-
Institute Gustave Roussy
Paris, France
-
The Institute of Cancer Research
Sutton, United Kingdom
-
University Carl Gustav Carus
Dresden, Germany
-
Universitätsklinikum Wuerzburg
Würzburg, Germany